Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic?
A type 1 diabetes patient experienced remission associated with chloroquine therapy while travelling to a malaria-endemic area. Chloroquine has immunomodulatory and hypoglycaemic effects and may become more frequently used due to the COVID-19 pandemic. Patients with type 1 diabetes treated with chlo...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12181
- Acceso en línea:
- https://www.sciencedirect.com/science/article/pii/S1871402120300795?via%3Dihub
http://hdl.handle.net/20.500.12010/12181
https://doi.org/10.1016/j.dsx.2020.04.014
- Palabra clave:
- Diabetes
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Type 1 diabetes
Chloroquine
Hypoglycaemia
Remission
- Rights
- License
- Acceso restringido
| Summary: | A type 1 diabetes patient experienced remission associated with chloroquine therapy while travelling to a malaria-endemic area. Chloroquine has immunomodulatory and hypoglycaemic effects and may become more frequently used due to the COVID-19 pandemic. Patients with type 1 diabetes treated with chloroquine should be monitored for hypoglycaemia, even after recovery. |
|---|